RxDoctor Payments Data

Nathan Neufeld, DO

Interventional Pain Medicine · Newnan, GANPI 1497993067

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $111,829 of the $170,964 with a category attached, or 65.4%. Medtronic accounts for 76.7% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $51,567 and has fallen 57.3% since, to $22,025 in 2025. Among interventional pain medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$170,964in general payments, 2019–2025

Across 284 payments — averaging $601.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$131K
  • Stryker$39K
  • Abbott$187
  • Averitas Pharma Inc.$140
  • SPR Therapeutics, Inc$81
  • Vertex$79
  • plus $303 from 12 others

What the payments were for

  • Consulting fees$37,90022%
  • Speaking & faculty fees$111,82965%
  • Grants$1510%
  • Travel & lodging$13,8368%
  • Food & beverage$7,2204%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$170,964 in reported general payments places this provider in the 95th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$64,269
Medicare patients
173
Services billed
579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate25$15,153
Oxycodone Hcl159$5,259
Fentanyl25$2,830
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen97$2,687
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen56$1,939
Gabapentin106$1,383
Pregabalin76$1,133
Morphine Sulfate ErMorphine Sulfate37$829
Morphine Sulfate13$451
Nortriptyline Hcl30$430
Hydromorphone Hcl18$375
Cyclobenzaprine Hcl34$301
Methadone Hcl22$290
Duloxetine Hcl38$275
Tizanidine Hcl57$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$22$15,15325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →